Transthyretin Amyloid Cardiomyopathy (ATTR-CM)—
Total Page:16
File Type:pdf, Size:1020Kb
BIOEQUIVALENCE / VYNDALINK / REFS When you’ve decided VYNDAMAX is appropriate for your patient, VyndaLink may be able to help ATTR-CM is a progressive, fatal Enroll your patients in VyndaLink for support or send prescriptions directly to an in-network Specialty Pharmacy disease—recognize the signs The VyndaLink team can: and symptoms to diagnose and treat 2,3 Conduct a benefits verification to Determine payer requirements and Identify Specialty Pharmacy options based your appropriate patients determine your patient’s coverage provide information about the prior on your patient’s insurance coverage. Transthyretin amyloid for VYNDAMAX, including out-of- authorization process and appeals VYNDAMAX is available through multiple pocket costs. process as needed.* Specialty Pharmacies in our defined distribution network. VYNDAMAX—once-daily, oral medication for patients with wild-type or hereditary ATTR-CM *Please note where a PA is required, the physician must submit required information directly to the patient’s insurer. cardiomyopathy (ATTR-CM)— Get started at www.VyndaLink.com a disease that may be present in Download the enrollment form. Completed form can be sent online at www.VyndaLinkPortal.com or Proven to reduce mortality and 1 AM PM patients with heart failure faxed to 1-888-878-8474. Call 1-888-222-8475 (Monday-Friday, 8 -8 ET) with any questions. CV-related hospitalization Consider prescribing oral VYNDAMAX for References: 1. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018;33(5):571-579. 2. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid bril proteins and amyloidosis: chemical identication and clinical classication International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209-213. 3. Narotsky DL, Castano A, Weinsaft JW, Bokhari S, Maurer MS. Wild-type transthyretin cardiac amyloidosis: novel insights from advanced imaging. Can J Cardiol. 2016;32(9):1166.e1-1166.e10. 4. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. patients with wild-type or hereditary ATTR-CM Circulation. 2017;135(14):1357-1377. 5. Brunjes DL, Castano A, Clemons A, Rubin J, Maurer MS. Transthyretin cardiac amyloidosis in older Americans. J Card Fail. 2016;22(12):996-1003. 6. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on A safety prole similar to placebo pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28(1):10-21. 7. Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;63(2):161-172. 8. González-López E, López-Sainz A, Garcia-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis. Rev Esp Cardiol. 2017;70(11):991-1004. 9. Reynolds M, Veverka K, Gertz M, et al. Ocular manifestations of familial transthyretin amyloidosis. Am J Ophthalmol. 2017;183:156-162. 10. Rubin J, Alvarez J, Teruya S, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloidosis: can we affected patients earlier? Amyloid. 2017;24(4):224-228. 11. Dang J, Abulizi M, Mokte A, et al. Renal infarction and its consequences for renal function in patients with cardiac amyloidosis. Mayo Clin Proc. 2019. doi:10.1016/j.mayocp.2019.02.012 12. Khalighi MA, ATTR-CM=transthyretin amyloid cardiomyopathy; CV=cardiovascular. Dean Wallace W, Palma-Diaz MF. Amyloid nephropathy. Clin Kidney J. 2014;7(2):97-106. 13. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412. 14. Bokhari S, Morgenstern R, Weinberg R, et al. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J Nucl Cardiol. 2018;25(1):181-190. 15. American Society of Nuclear Cardiology (ASNC). ASNC cardiac amyloidosis practice points: 99mtechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. Available at: https://www.asnc.org/les/19110 ASNC Amyloid Practice Points WEB(2).pdf Published February 2016. Updated February 2019. Accessed November 8, 2019. 16. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. 17. Tankisheva E. A phase 1, open-label, randomized, crossover, multiple dose, pivotal bioequivalence INDICATION INDICATION study to compare PF-06291826 4 × 20 mg tafamidis meglumine and 61 mg: tafamidis free acid soft gelatin capsules administered under fasted conditions to healthy volunteers. Full Clinical Study Report [protocol B3461056]. July 23, 2018. 18. Data on le. VYNDAQEL® (tafamidis meglumine) and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or VYNDAQEL® (tafamidis meglumine) and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or Pzer Inc., New York, NY. hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION (continued) Adverse Reactions Adverse Reactions Specific Populations In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL was similar to placebo. In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL was similar to placebo. Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to Specific Populations Specific Populations a pregnant woman. Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the a pregnant woman. a pregnant woman. Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX. present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX. present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX. Please see accompanying Full Prescribing Information including Patient Information at the end of this document. Please see accompanying Full Prescribing Information including Patient Information at the end of this document. Please see accompanying Full Prescribing Information including Patient Information at the end of this document. PP-VDM-USA-0194 © 2020 Pzer Inc. All rights reserved. Prescription only. March 2020 ABOUT ATTR-CM / FULL PRESCRIBING INFORMATION, INCLUDING PATIENT INFORMATION SYMPTOMS Transthyretin amyloid cardiomyopathy—a fatal, underdiagnosed cardiomyopathy caused by Signs and symptoms that may present in patients with ATTR-CM1,3-12 aggregated misfolded proteins, called amyloid fibrils, that accumulate in the myocardium1-3 Transthyretin amyloid cardiomyopathy— Cardiovascular Ocular a fatal, underdiagnosed cardiomyopathy • Heart failure • Vitreous opacity caused by aggregated misfolded proteins, • Intolerance to standard HF • Glaucoma Subtypes of ATTR-CM1,2: Patients present with symptoms of heart failure and may called amyloid fibrils, that accumulate in the therapies 1-3 • Low voltage relative to LV also present with other manifestations, such as atrial myocardium thickness Musculoskeletal/Orthopedic —Wild-type ATTR (wtATTR) 3,4 fibrillation and carpal tunnel syndrome, often bilateral • Echocardiography showing • Biceps tendon rupture —Hereditary ATTR (hATTR) increased LV wall thickness • Lumbar spinal stenosis • Cardiac arrhythmia • Carpal tunnel syndrome » In the United States, Val122lle and Thr60Ala are the Patients with ATTR-CM may also present • Aortic stenosis • Hip/knee arthroplasty most common mutations that typically manifest as Once diagnosed, untreated patients have a median survival with noncardiac manifestations that may not cardiomyopathy symptoms4 of ~2 to 3.5 years4 typically be present in other cardiovascular Nervous system diseases4 Autonomic Renal • Autonomic neuropathy • Renal impairment • Gastrointestinal complaints • Cardiorenal syndrome Transthyretin amyloid cardiomyopathy is frequently • Unexplained weight loss misdiagnosed, and delayed diagnosis can lead to significant Please note, VYNDAMAX is not indicated to • Orthostatic hypotension clinical consequences for patients4 treat all of the symptoms of ATTR-CM shown • Sexual